Emageon extends backlog, strikes credit deal

Article

Current contracts signed by PACS and IT developer Emageon have extended the company's backlog of orders to a figure in excess of $100 million. Emageon attributes much of its success to partnering with large integrated delivery networks (IDNs), including

Current contracts signed by PACS and IT developer Emageon have extended the company's backlog of orders to a figure in excess of $100 million. Emageon attributes much of its success to partnering with large integrated delivery networks (IDNs), including Kaiser Permanente, Sisters of Mercy, Sutter Health, Allina Hospitals and Clinics, and Aurora Health Care. To date, more than 70 acute care hospitals and imaging facilities have implemented Emageon products. The company, which expects to complete 30 additional hospital implementations this year, currently has a customer base of more than 250 sites. Supporting future growth is a new agreement with IBM that will allow Emageon customers to obtain IBM Global Financing, providing a single-source agreement for financing Emageon products and services.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.